KTX 1162
Alternative Names: KTX-1162Latest Information Update: 17 Nov 2023
At a glance
- Originator Kuria Therapeutics
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry age-related macular degeneration
Most Recent Events
- 26 Sep 2023 Preclinical trials in Dry age-related macular degeneration in USA (unspecified route), prior to September 2023 (Kuria Therapeutics pipeline, September 2023)
- 26 Sep 2023 Kuria Therapeutics plans a phase IIa SEACHANGE trial for Dry age-related macular degeneration in 2025 (Kuria Therapeutics pipeline, September 2023)
- 26 Sep 2023 Kuria Therapeutics plans a phase IIb SEACHANGE II trial for Dry age-related macular degeneration in 2027 (Kuria Therapeutics pipeline, September 2023)